Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies 
(DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network 
meta-analysis was conducted to determine the relative effect of ofatumumab on 
annualized relapse rate and confirmed disability progression at 3 months and 
6 months. Results: For each outcome, ofatumumab was as effective as other highly 
efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and 
ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by 
reducing relapse and disability progression risk.